Results 141 to 150 of about 6,192 (194)

Comment on "SMPDL3B as a novel biomarker and therapeutic target in myalgic encephalomyelitis" critical considerations on biomarker validation and Supraphysiological drug concentrations. [PDF]

J Transl Med
Chen J, Yan L.
europepmc   +1 more source

A case series of vildagliptin-associated bullous pemphigoid - Rare side effect.

Indian J Pharmacol
Shahi MK, Ashwin JV, Singh A, Gupta S, Surya K.   +4 more
europepmc   +1 more source

Authors' Response to "Comment on 'SMPDL3B as a novel biomarker and therapeutic target in myalgic encephalomyelitis'". [PDF]

J Transl Med
Rostami-Afshari B, Elremaly W, Franco A, Moreau A.   +3 more
europepmc   +1 more source

Combined experimental and computational investigation of vildagliptin: spectroscopy, electronic structure, MD and Docking to EGFR, VEGFR2, and HER2 anticancer targets. [PDF]

J Comput Aided Mol Des
Inglot TW.
europepmc   +1 more source

Cardiovascular Sequel in Type-2 Diabetes Mellitus Patients on Various Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systemic Review and Meta-Analysis. [PDF]

Cureus
Prakash V, Goel N.
europepmc   +1 more source

Unusual Presentation of Bullous Pemphigoid as Erythroderma in an Elderly Male. [PDF]

Indian Dermatol Online J
Thind A, Stephen, Singh A, Kaur S.
europepmc   +1 more source

Comparison of renal function of the patients receiving linagliptin or vildagliptin in uncontrolled type 2 diabetes mellitus: An observational study in the backdrop of the COVID-19 pandemic.

Indian J Pharmacol
Chaudhuri S, Biswas S, Mukhopadhyay S, Dasgupta S.   +3 more
europepmc   +1 more source

Efficacy and Safety of Once-Weekly Trelagliptin As Compared to Twice-Daily Vildagliptin in Indian Patients With Type 2 Diabetes Mellitus: A Randomized, Phase 3, Non-inferiority Clinical Trial. [PDF]

Cureus
Dewan B, Shinde S, Roy S.
europepmc   +1 more source

SGLT2 Inhibitors and the Risk of Infections in Type 2 Diabetes: Systematic Review and Meta-Analyses of Real-World Evidence. [PDF]

J Diabetes Res
Alfonso Arvez MJ, Tan GSQ, Leung MTY, Ademi Z, Bell JS.   +4 more
europepmc   +1 more source

Correction: Unravelling the mechanism by which vildagliptin and linagliptin inhibit pyroptosis in lung injury through the NLRP3 inflammatory pathway in type 1 diabetic rats. [PDF]

Sci Rep
Sedik AA, El-Nasr NMEA, Khalil WKB, El-Mosallamy AEMK.   +3 more
europepmc   +1 more source